About lurbinecte din
Antineoplastic alkylating agent
Used for
- Treats adults with metastatic small-cell lung cancer after platinum-based chemotherapy.
Usual adult dose
3.2 mg/m² by intravenous infusion over one hour every 21 days, with dexamethasone premedication.
Common side effects
- Low blood cell counts
- Nausea and vomiting
- Fatigue
- Liver enzyme increases
Important warnings
- Can cause severe bone marrow suppression and serious infections.
- May cause liver injury; liver tests are monitored.
- Can cause muscle injury, including rhabdomyolysis.
- Can harm an unborn baby; effective contraception is required.
Pregnancy
May cause fetal harm. Avoid during pregnancy; use effective contraception during treatment and for six months afterward.
Breastfeeding
Breastfeeding is not recommended during treatment or for two weeks after the last dose.
Interactions
- Strong CYP3A inhibitors can increase exposure and toxicity.
- Strong CYP3A inducers can reduce effectiveness.
- Avoid grapefruit and grapefruit juice, which may affect drug levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.